Posted: Friday, May 7, 2021. 10:31 am CST.
By Zoila Palma: Medicine regulators in Europe are currently reviewing reports of a rare nerve disorder after the AstraZeneca COVID-19 shot.
The safety committee of the European Medicines Agency (EMA) is analyzing data provided by AstraZeneca on cases of Guillain-Barre syndrome (GBS), Reuters report.
The review comes after last month, the EMA found that both AstraZeneca and Johnson & Johnson (JNJ.N) may have caused very rare blood clotting cases.
The regulator has joined the WHO in saying that the benefits of the AstraZeneca shot outweigh potential risks, several European countries have limited use to older age groups or suspended use altogether.
GBS is a rare neurological condition in which the body’s immune system attacks the protective coating on nerve fibers. Most cases follow a bacterial or viral infection.
In addition, there are reports of heart inflammation with Pfizer-BioNTech’s (PFE.N), (22UAy.DE) vaccine, and Moderna’s (MRNA.O) shot, that the committee is also reviewing.
Advertise with the mоѕt vіѕіtеd nеwѕ ѕіtе іn Belize ~ We offer fully customizable and flexible digital marketing packages. Your content is delivered instantly to thousands of users in Belize and abroad! Contact us at mаrkеtі[email protected]еаkіngbеlіzеnеwѕ.соm or call us at 501-601-0315.
© 2021, BreakingBelizeNews.com. Content is copyrighted and requires written permission for reprinting in online or print media. Theft of content without permission/payment is punishable by law.